(BUSINESS WIRE)--Merck (known as MSD outside the United States and Canada) today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.
